# Alterity Therapeutics Limited > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alterity Therapeutics Limited). ## Overview Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders, particularly Multiple System Atrophy (MSA) and related Parkinsonian diseases. The company is based in Melbourne, Australia with an additional presence in San Francisco, USA, and advances its programs through clinical development and a drug-discovery platform. ## Products & services • ATH434 lead clinical program for Multiple System Atrophy • Disease-modifying therapies for Parkinsonian disorders • Clinical development of neurodegenerative disease candidates • Neurological drug discovery platform and novel chemical compounds - **Lead clinical asset** (70%) — ATH434 and related clinical-stage development activities in MSA. - **Neurological pipeline** (15%) — Earlier-stage programs targeting neurodegenerative disease biology. - **Drug discovery platform** (15%) — Discovery work generating patentable compounds for neurological diseases. - ATH434 lead clinical program for Multiple System Atrophy - Disease-modifying therapies for Parkinsonian disorders - Clinical development of neurodegenerative disease candidates - Neurological drug discovery platform and novel chemical compounds ## Customers Alterity does not sell commercial products to end consumers; its primary stakeholders are clinical investigators, trial sites, regulators, and future prescribing neurologists who would use approved therapies. In the current stage, the 'customer' is effectively the medical community and clinical-trial ecosystem that supports development and validation of its drug candidates. - **Clinical investigators and trial sites** (primary) — They enroll patients and execute MSA and Parkinsonian-disorder trials to generate efficacy and safety data. - **Neurologists and movement-disorder specialists** (primary) — They are the eventual prescribers of any approved neurodegenerative-disease therapy. - **Regulators and ethics committees** (primary) — They review trial design, safety, and quality data before and during development. - **Patients and caregivers** (secondary) — They participate in clinical studies and represent the unmet need the pipeline is designed to address. - Clinical investigators and trial sites running MSA studies - Neurologists treating rare neurodegenerative disorders - Regulators reviewing safety and efficacy data - Future specialty-pharmacy and hospital channels after approval ## Geography Alterity is headquartered in Melbourne, Australia and also operates from San Francisco, USA. Its clinical and investor activity spans Australia and the United States, reflecting a cross-border biotech structure with U.S. capital markets access through NASDAQ and ASX listing presence. - Headquartered in Melbourne, Australia - Operates from San Francisco, California - Clinical development and investor outreach span Australia and the U.S. - Listed on ASX and NASDAQ, supporting dual-market visibility ## Strategy Alterity's core strategy is to advance ATH434 through late-stage clinical development in MSA, a rare disease with significant unmet need. It also maintains a discovery platform to extend its pipeline into related neurological diseases and create follow-on assets beyond the lead program. - **Progress ATH434 through late-stage MSA development** (short-term) — The lead asset is the main value driver and the clearest path to clinical validation. - **Broaden clinical relevance across Parkinsonian disorders** (medium-term) — A broader label opportunity can expand the addressable market and support platform value. - **Sustain discovery output from the chemistry platform** (long-term) — Pipeline depth reduces dependence on a single asset and creates future partnering options. - Advance ATH434 toward pivotal clinical development in MSA - Build evidence in related Parkinsonian disorders - Use clinical data to support differentiation in rare neurodegeneration - Maintain a discovery engine for new neurological candidates ## Risks The company faces the typical clinical-stage biotech risks of trial failure, safety signals, regulatory delay, and uncertain translation from Phase 2 results into pivotal outcomes. Because Alterity depends heavily on a small number of neurological programs, execution risk around ATH434 and financing for development remain central. - **Clinical development failure** [critical] — Therapeutic candidates may not reproduce Phase 2 efficacy or may fail pivotal endpoints. - **Regulatory and trial execution delays** [high] — Rare-disease studies depend on site activation, enrollment, and regulator alignment. - **Financing dilution** [high] — Clinical-stage biotechnology typically requires repeated capital raising before commercialization. - **Pipeline concentration** [high] — A limited number of programs increases the impact of any setback in the lead asset. - Phase 3 trial risk if ATH434 fails to confirm Phase 2 signals - Safety or tolerability issues in rare-disease patient populations - Regulatory and clinical-enrollment delays in MSA studies - Concentration risk from dependence on a single lead asset - Ongoing funding needs typical of clinical-stage biotechnology ## Accounting As a clinical-stage biotech, Alterity's reported numbers are shaped by R&D expense recognition, capitalization or expense treatment of development costs, and judgment around share-based compensation. Its periodic cash reports also highlight funding runway, making cash burn and equity issuance important to interpret alongside the income statement and balance sheet. - **Research and development expense** — Affects operating loss and cash burn - **Share-based compensation** — Raises non-cash operating expenses and weakens comparability - **Equity issuance and dilution** — Changes share count and per-share valuation metrics - **Runway and going-concern judgments** — Influences liquidity interpretation and financing risk - Research and development expense drives period losses and cash burn - Share-based compensation can materially affect operating expenses - Capital raises and option exercises affect equity and dilution - Going-concern and runway judgments matter for investor analysis --- *Last updated: 2026-09-28T11:57:30.373005+00:00*